NZ505994A - Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases - Google Patents

Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases

Info

Publication number
NZ505994A
NZ505994A NZ505994A NZ50599498A NZ505994A NZ 505994 A NZ505994 A NZ 505994A NZ 505994 A NZ505994 A NZ 505994A NZ 50599498 A NZ50599498 A NZ 50599498A NZ 505994 A NZ505994 A NZ 505994A
Authority
NZ
New Zealand
Prior art keywords
statin
matrix metalloproteinase
vascular diseases
metalloproteinase inhibitor
treating vascular
Prior art date
Application number
NZ505994A
Inventor
Roger Schofield Newton
Bruce David Roth
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ505994A publication Critical patent/NZ505994A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A pharmaceutical composition contains: a MMP inhibitor or a salt thereof of formula (I) wherein A is phenyl, piperidinyl or piperazinyl; R1 is alkyl, aryl, halo, optionally substituted amino or alkoxy and R2 is carboxyalkyl ketone, carboxyalkyl sulphonamide or oxime; a statin or a salt thereof and a pharmaceutically carrier or diluent. The MMP inhibitor of formula (I) is used in the manufacture of a medicament to treat hyperlipidemia.
NZ505994A 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases NZ505994A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17
PCT/US1998/024681 WO1999047138A1 (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations

Publications (1)

Publication Number Publication Date
NZ505994A true NZ505994A (en) 2003-10-31

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ505994A NZ505994A (en) 1998-03-17 1998-11-20 Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases

Country Status (18)

Country Link
EP (1) EP1063991A1 (en)
JP (1) JP2002506818A (en)
KR (1) KR20010041916A (en)
AR (1) AR018113A1 (en)
AU (1) AU1591699A (en)
BR (1) BR9815745A (en)
CA (1) CA2309588A1 (en)
CO (1) CO5070670A1 (en)
GT (1) GT199900039A (en)
HN (1) HN1999000029A (en)
MY (1) MY140504A (en)
NZ (1) NZ505994A (en)
PA (1) PA8469001A1 (en)
PE (1) PE20000348A1 (en)
SV (1) SV1999000026A (en)
UY (1) UY25436A1 (en)
WO (1) WO1999047138A1 (en)
ZA (1) ZA992106B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP2008524159A (en) 2004-12-15 2008-07-10 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition comprising NEP inhibitor, endogenous endothelin production system inhibitor and HMGCoA reductase inhibitor
EP1948599A1 (en) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636783T2 (en) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION
SK282863B6 (en) * 1996-05-17 2002-12-03 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.

Also Published As

Publication number Publication date
CA2309588A1 (en) 1999-09-23
GT199900039A (en) 2000-09-06
HN1999000029A (en) 1999-09-29
SV1999000026A (en) 2000-01-18
UY25436A1 (en) 2001-10-25
MY140504A (en) 2009-12-31
BR9815745A (en) 2000-11-14
AU1591699A (en) 1999-10-11
KR20010041916A (en) 2001-05-25
PA8469001A1 (en) 2002-09-17
WO1999047138A1 (en) 1999-09-23
ZA992106B (en) 1999-09-30
EP1063991A1 (en) 2001-01-03
JP2002506818A (en) 2002-03-05
PE20000348A1 (en) 2000-05-22
AR018113A1 (en) 2001-10-31
CO5070670A1 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
GB9801690D0 (en) Therapeutic agents
NO996269L (en) Quinoline-indole antimicrobial agents, as well as the use and mixtures thereof
GB2392154B (en) Protein Kinase Inhibitors
NO934719D0 (en) HIV protease inhibitors useful for the treatment of AIDS
FI956119A (en) Phenyl heterocycles as cyclooxygenase-2 inhibitors
NO20002440L (en) Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity
EP1566379A4 (en) QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
FI935777A0 (en) Inhibitor Foer HIV-Proteas can be used to treat AIDS
NZ505994A (en) Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
GR3022604T3 (en) Inhibitors of hiv protease useful for the treatment of aids.
DE60005517D1 (en) POTASS CHANNEL BLOCKING AGENTS
BR9606429A (en) Compound composition and process for treatment of dysfunction mediated by uPar- or uPa-
MXPA03000337A (en) Thrombin inhibitors comprising an aminoisoquinoline group.
SE9704770D0 (en) New use
MY136928A (en) New isoquinoline compounds, a process for their preparation and pharmaceutical composition containing them
SE0004827D0 (en) Therapeutic compounds
SE0102058D0 (en) New Salts II
EP1200089A4 (en) Pyridomorphinans and use thereof
DE69808326D1 (en) AZETIDINE DERIVATIVES FOR TREATING HCMV INFLAMMATION
DE69619088D1 (en) Quinoxaline derivatives used to treat tinnitus
BR0009944A (en) Cysteine protease and inhibitors for the prevention and treatment of neurocysticercosis
DK0673913T3 (en) Calcium-alkali metal citrate compounds as well as their use as drugs
ATE229804T1 (en) ANTIBACTERIAL CARBAPENEMS, COMPOSITIONS AND METHODS OF TREATMENT

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed